TY - JOUR
T1 - Extended-release naltrexone plus medical management alcohol treatment in primary care
T2 - Findings at 15 months
AU - Lee, Joshua D.
AU - Grossman, Ellie
AU - Huben, Laura
AU - Manseau, Marc
AU - McNeely, Jennifer
AU - Rotrosen, John
AU - Stevens, David
AU - Gourevitch, Marc N.
N1 - Funding Information:
Grant support and study drug product was provided by Alkermes, Inc. , through an Investigator Sponsored Study mechanism. We would like to acknowledge the efforts in support of and involvement in this study by Les Chuang MD, Kathleen Hanley MD, Valerie Perel MD, Andrea Truncali MD, and Andrew Wallach MD.
PY - 2012/12
Y1 - 2012/12
N2 - The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).
AB - The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).
KW - Alcohol medical management
KW - Alcohol pharmacotherapy
KW - Alcohol treatment
KW - Extended-release naltrexone
KW - Primary care
UR - http://www.scopus.com/inward/record.url?scp=84868142386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868142386&partnerID=8YFLogxK
U2 - 10.1016/j.jsat.2012.08.012
DO - 10.1016/j.jsat.2012.08.012
M3 - Article
C2 - 22985676
AN - SCOPUS:84868142386
SN - 0740-5472
VL - 43
SP - 458
EP - 462
JO - Journal of Substance Abuse Treatment
JF - Journal of Substance Abuse Treatment
IS - 4
ER -